3. Umbruch 4.4..2005 - Online Pot

250 G.W. Guy and C.G. Stott
Figure 8. Relief of sleep disturbance [50, 51, 55–58, 60]
Figure 9. Sustained relief of neuropathic pain [64]
Scale (range 0–10). A summary of the results is given below, and the primary
endpoint presented in Figure 4.
Sixty-four patients (96.9%) completed the trial. Fourteen patients were
male, mean age 49.2 years (range 26.9–71.4, SD 8.3), mean expanded disability
status scale (EDSS) 5.9 (range 2.0–8.5, SD 1.3) and mean duration of
MS since diagnosis 11.5 years (range 1–36, SD 7.7).
The mean number of daily sprays taken in the final week of treatment was 9.6
of Sativex ® (range 2–25, SD 6.1) and 19.1 of placebo (range 1–47, SD 12.9).
Thirty patients (88.2%) on Sativex ® and 22 (68.8%) on placebo had at least
one adverse event, none of which were serious. There was a statistically significant
mean reduction in pain in favour of Sativex ® , as measured using the